Icosavax, Inc. (ICVX) Research

Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.

Market snapshot

Symbol
ICVX
Price
$15.31
Day change
-0.91%
Market cap
$769.0M
P/E ratio
-6.88x
52-week range
4.75-16.105
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$27.00

Peer companies

  • Albireo Pharma, Inc. (ALBO)
  • ASLAN Pharmaceuticals Limited (ASLN)
  • Avid Bioservices, Inc. (CDMO)
  • Chimerix, Inc. (CMRX)
  • Exscientia plc (EXAI)
  • Harpoon Therapeutics, Inc. (HARP)
  • Intercept Pharmaceuticals, Inc. (ICPT)
  • Ikena Oncology, Inc. (IKNA)

Recent insider activity

  • RA CAPITAL MANAGEMENT, L.P. — D-Return (17000 shares) on 2024-02-19
  • RA CAPITAL MANAGEMENT, L.P. — U-Tender (638668 shares) on 2024-02-19
  • RA CAPITAL MANAGEMENT, L.P. — D-Return (22278 shares) on 2024-02-19
  • Simpson Adam K. — U-Tender (129032 shares) on 2024-02-19
  • Simpson Adam K. — D-Return (317866 shares) on 2024-02-19

Open Icosavax, Inc. (ICVX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.